Alzheimer’s Drug Discovery Foundation
Dr. Howard Fillit is ADDF’s Founding Executive Director and Chief Science Officer. His introduction will provide a welcome to our 21st International Conference on Alzheimer’s Drug Discovery, a brief update on ADDF’s recent progress and will highlight the framework for this year’s meeting.
Weill Cornell Medical College
University of Gothenburg
Gene Therapy for Neurodegeneration
Current State for Blood Biomarkers in AD
SESSION I: Novel Approaches for Neuroinflammation
The field continues to learn more about the role that inflammation plays in the progression of Alzheimer’s pathology. This session highlights preclinical drug development, clinical trials and an imaging agent in development to target various aspects of neuroinflammation.
Linda Van Eldik
University of Kentucky
Johns Hopkins University
SESSION II: Metabolic and Mitochondrial Approaches for Alzheimer’s Disease
Mounting evidence suggests that energy dysregulation in the form of metabolic or mitochondrial changes can contribute to the progression of Alzheimer’s disease. This session features a company developing innovative new drugs targeting mitochondria and the presentation of two completed clinical trials in the space.
Burke Neurological Inst.
SESSION III: Emerging Areas in Drug Development for Neurodegeneration
The ADDF closely follows emerging areas of aging biology that could be targeted to halt, prevent and cure Alzheimer’s and related dementias. This session will feature overviews of some of these promising areas which include cellular senescence, autophagy and vascular contributions to dementia.
NS Kline Inst.
SESSION IV: Neuroprotection, Synaptic Health and Neurotransmitters
Synaptic and neuronal degeneration have been linked to the cognitive decline experienced in Alzheimer’s and related dementias. This session underscores the innovative work in neuroprotection featuring new progress from companies and in academic labs as well as the results from two completed clinical trials.
SESSION V: Novel Biomarkers in Alzheimer’s Disease
Biomarkers play an important role in many aspects of clinical care and development including diagnosis, prognosis, clinical trial enrollment, enrichment, monitoring and outcomes. This session will feature some of the most promising emerging fluid, digital and imaging biomarkers in development for Alzheimer’s disease.
The Rockefeller Univ.
UC San Diego
SESSION VI: VIRTUAL POSTER PRESENTATIONS
This session will feature research from early investigators in the academic community focused on drug development for Alzheimer’s and related dementias.
SESSION VII: START-UP FORUM
This session will feature drug development programs being pursued by start-up companies.